Dhiti Omics
Dhiti Omics is a Private Indian company incorporated in 2014 and based in Karnataka, India. Dhiti Omics operates in Pharmaceuticals & Chemicals (NIC 24100) with authorized capital of —. RegisterKaro's Compliance Health Score for the company is 30/100 (grade F), reflecting a weak compliance posture.
Dhiti Omics - Provides precision molecular diagnostic services. Raised a total funding of $278K over 2 rounds from 13 investors.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Dhiti Omics.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +10d | filed |
| MGT-7 | FY2024-25 | 24 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | +26d | filed |
| MGT-7 | FY2023-24 | 27 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 22 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Dhiti Omics.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 697765339 | HDFC Bank Ltd(Bank) | ₹15.72 Cr | 19 Sep 2019 | Open |
| 260386601 | Axis Bank Ltd(Bank) | ₹17.86 Cr | 27 Jan 2020 | Open |
| 695289425 | Kotak Mahindra Bank Ltd(Bank) | ₹5.96 Cr | 19 Sep 2021 | Open |
| 213703986 | State Bank of India(Bank) | ₹16.88 Cr | 19 Sep 2022 | Open |
| 310905905 | Kotak Mahindra Bank Ltd(Bank) | ₹24.42 Cr | 27 Jan 2023 | Open |
Charge IDs, lenders & amounts for Dhiti Omics.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
Locked| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| FY2024-25 | ₹27.70 Cr | ₹2.80 Cr | ₹16.45 Cr | ₹42.97 Cr | 104 |
| FY2023-24 | ₹21.78 Cr | ₹2.45 Cr | ₹11.63 Cr | ₹29.69 Cr | 25 |
| FY2022-23 | ₹19.20 Cr | ₹2.02 Cr | ₹10.30 Cr | ₹26.00 Cr | 35 |
| FY2021-22 | ₹17.66 Cr | ₹1.90 Cr | ₹10.27 Cr | ₹17.66 Cr | 153 |
Audited financials & ratios for Dhiti Omics.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Detailed Financials
Locked| Line item | FY2024-25 | FY2023-24 | FY2022-23 | FY2021-22 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ₹27.70 Cr | ₹21.78 Cr | ₹19.20 Cr | ₹17.66 Cr |
| Other income | ₹95.03 L | ₹63.33 L | ₹36.40 L | ₹55.26 L |
| Total income | ₹28.65 Cr | ₹22.41 Cr | ₹19.57 Cr | ₹18.21 Cr |
| Total expenses | ₹25.07 Cr | ₹19.27 Cr | ₹16.98 Cr | ₹15.78 Cr |
| Profit before tax | ₹3.64 Cr | ₹3.19 Cr | ₹2.63 Cr | ₹2.47 Cr |
| Profit / (Loss) after tax | ₹2.80 Cr | ₹2.45 Cr | ₹2.02 Cr | ₹1.90 Cr |
| Balance sheet | ||||
| Equity / Net worth | ₹16.45 Cr | ₹11.63 Cr | ₹10.30 Cr | ₹10.27 Cr |
| Borrowings | ₹9.36 Cr | ₹7.15 Cr | ₹4.21 Cr | ₹2.91 Cr |
| Current liabilities | ₹14.32 Cr | ₹8.16 Cr | ₹8.25 Cr | ₹3.48 Cr |
| Total liabilities | ₹26.52 Cr | ₹18.06 Cr | ₹15.70 Cr | ₹7.39 Cr |
| Current assets | ₹16.86 Cr | ₹16.16 Cr | ₹14.85 Cr | ₹6.98 Cr |
| Cash & equivalents | ₹3.28 Cr | ₹4.77 Cr | ₹4.32 Cr | ₹2.08 Cr |
| Total assets | ₹42.97 Cr | ₹29.69 Cr | ₹26.00 Cr | ₹17.66 Cr |
| Employees | 104 | 25 | 35 | 153 |
Audited financials & ratios for Dhiti Omics.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Compounded Annual Growth Rate
Locked| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue | ₹27.70 Cr | +19.7% | +20.6% | +0.1% |
| Profit after Tax | ₹2.80 Cr | +18.4% | +24.2% | +19.9% |
| Net Worth | ₹16.45 Cr | +32.5% | -0.9% | +15.2% |
| Employees | 104 | +16.5% | +26.9% | +2.8% |
Audited financials & ratios for Dhiti Omics.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Financial Ratios
Locked| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| FY2024-25 | ₹27.70 Cr | ₹2.80 Cr | +10.10% | +16.57% | +17.01% | +6.51% | 0.57 | ₹26.63 L |
| FY2023-24 | ₹21.78 Cr | ₹2.45 Cr | +11.27% | +2.92% | +21.09% | +8.26% | 0.61 | ₹87.12 L |
| FY2022-23 | ₹19.20 Cr | ₹2.02 Cr | +10.54% | +33.14% | +19.64% | +7.78% | 0.41 | ₹54.87 L |
| FY2021-22 | ₹17.66 Cr | ₹1.90 Cr | +10.77% | +30.55% | +18.53% | +10.77% | 0.28 | ₹11.54 L |
Audited financials & ratios for Dhiti Omics.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 4 | 2,26,69,657 | 57.55% |
| Institutional Investors | 2 | 8,63,683 | 2.19% |
| Public & Others | 48 | 1,58,59,799 | 40.26% |
Promoter, institutional & public holding for Dhiti Omics.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
34 peersEvents & timeline
1External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.